Galantamine prevents apoptosis induced by β-amyloid and thapsigargin: Involvement of nicotinic acetylcholine receptors

Neuropharmacology

Volumn 46, Issue 1, 2004, Pages 103-114

  Arias, Esperanza ^a   Alés, Eva ^a   Gabilan, Nelson H ^b   Cano Abad, María F ^a   Villarroya, Mercedes ^a   García, Antonio G ^a,c   López, Manuela G ^a,c  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^c HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

Apoptosis; Bcl 2; Galantamine; Neuroprotection; Nicotinic receptors; Thapsigargin; amyloid

Indexed keywords

ALPHA BUNGAROTOXIN; AMYLOID BETA PROTEIN; CALCIUM ION; FURA 2; GALANTAMINE; NICOTINIC RECEPTOR; PROTEIN BCL 2; THAPSIGARGIN;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CATTLE; CELL TYPE; CHROMAFFIN CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOSOL; HUMAN; HUMAN CELL; INCUBATION TIME; NEUROBLASTOMA CELL; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RECEPTOR DENSITY; UPREGULATION;

EID: 0344688198     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(03)00317-4     Document Type: Article

References (46)

1. Albuquerque E.X., Pereira E.F., Alkondon M., Schrattenholz A., Maelicke A. Nicotinic acetylcholine receptors on hippocampal neurons: distribution on the neuronal surface and modulation of receptor activity. Journal of Receptors and Signal Transduction Research. 17:1997;243-266.
2. Belluardo N., Mudo G., Blum M., Fuxe K. Central nicotinic receptors, neurotrophic factor and neuroprotection. Behavior Brain Research. 113:2000;21-34.
3. Blesa R., Davidson M., Kurz A., Reichman W., Van Baelen B., Schwalen S. Galantamine provides sustained benefits in patients with "advanced moderate" Alzheimer's disease for at least 12 months. Demential Geriatric Cognition Disorders. 15:2003;79-87.
4. Bonner L.T., Peskind E.R. Pharmacologic treatment of dementia. Medical Clinics of North America. 86:2002;657-674.
5. Capsoni S., Giannotta S., Cattaneo A. Nerve growth factor and galantamine ameliorate early signs of neurodegeneration in anti-nerve growth factor mice. Proceedings of the National Academy of Sciences USA. 99:2002;12432-12437.
6. Criado M., Alamo L., Navarro A. Primary structure of an agonist binding subunit of the nicotinic acetylcholine receptor from bovine adrenal chromaffin cells. Neurochemistry Research. 17:1992;281-287.
7. Criado M., Domínguez del Toro E., Carrasco-Serrano C., Smillie F.I., Juiz J.M., Viniegra S., Ballesta J.J. Differential expresion of alpha-bungarotoxin-sensitive neuronal nicotinic receptors in adrenergic chromaffin cells: a role for transcription factor Egr-1. Journal of Neuroscience. 17:1997;6554-6564.
8. Donnelly-Roberts D.L., Brioni J.D. Preclinical evidence on the neuroprotective effects of nicotinic ligands. Arneric S.P., Brioni J.D. Neuronal Nicotinic Receptors Pharmacology and Therapeutic Opportunities. 1998;337-348 Wiley-Liss, Inc.
9. Donnelly-Roberts D.L., Xue I.C., Arneric S.P., Sullivan J.P. In vitro neuroprotective properties of the novel cholinergic channels activator (ChCA), ABT-418. Brain Research. 719:1996;36-44.
10. Fucile S., Lax P., Eusebi F. Nicotine modulates the spontaneous synaptic activity in cultured embryonic rat spinal cord interneurons. Journal of Neuroscience Research. 67:2002;329-336.
11. Franklin J.L., Johnson E.M. Jr. Suppression of programmed neuronal death by sustained elevation of cytoplasmic calcium. Trends in Neuroscience. 15:1992;501-508.
12. Gould J., Reeve H.L., Vaughan P.F., Peers C. Nicotinic acetylcholine receptors in human neuroblastoma (SH-SY5Y) cells. Neuroscience Letters. 145:1992;201-204.
13. Grynkiewicz G., Poenie M., Tsien R.Y. A new generation of calcium indicators with greatly improved fluorescence properties. Journal of Biological Chemistry. 260:1985;3440-3450.
14. Hamill O.P., Marty A., Neher E., Sackmann B., Sigwoth F.J. Improved patch-clamp techniques for high resolution current recording from cells and cell-free membrane patches. Pflügers Archives. 391:1981;85.
15. Jellinger K.A., Stadelmann C. Problems of cell death in neurodegeneration and Alzheimer's disease. Journal of Alzheimers Disease. 3:2001;31-40.
16. Jonnala R.R., Buccafusco J.J. Relationship between the increased cell surface alpha7 nicotinic receptor expression and neuroprotection induced by several nicotinic receptor agonists. Journal of Neuroscience Research. 66:2001;565-572.
17. Kihara T., Shimohama S., Sawada H., Kimura J., Kume T., Kochiyama H., Maeda T., Akaike A. Nicotinic receptor stimulation protects neurons against β-amyloid toxicity. Annals of Neurology. 42:1997;159-163.
18. Kihara T., Shimohama S., Sawada H., Honda K., Nakamizo T., Shibasaki H., Kume T., Akaike A. Alpha7 nicotinic receptor transduces signals PI3 kinase to block A (-induced neurotoxicity. Journal of Biological Chemistry. 276:2001;13541-13546.
19. Lazarewicz M., Spiros A., Finkel L., Carr R., Geerts H. Understanding the dual mode of action of galantamine using a virtual synaptic cleft. Eighth International Conference of Alzheimer's Disease and Related Disorders, Stockholm: 2002;. abst. 447.
20. Lopez M.G., Montiel C., Herrero C.J., Garcia-Palomero E., Mayorgas I., Hernandez-Guijo J., Villarroya M., Olivares R., Gandia L., McIntosh M., Olivera B., Garcia A.G. Unmasking the functions of the chromaffin cell α7 nicotinic receptor by using short pulses of acetylcholine and selective blockers. Proceedings of the National Academy of Sciences USA. 95:1998;14184-14189.
21. Moro M.A., Lopez M.G., Gandia L., Michelena P., Garcia A.G. Separation and culture of living adrenaline- and noradrenaline-containing cells from bovine adrenal medullae. Analytical Biochemistry. 185:1990;243-248.
22. Nath R., Raser K.J., Hajimohammadreza I., Wang K.K. Thapsigargin induces apoptosis in SH-SY5Y neuroblastoma cells and cerebrocortical cultures. Biochemistry and Molecular Biology International. 43:1997;197-205.
23. Neher E. Combined fura-2 and patch-clamp measurements in rat peritoneal mast cell. Sellin L.P., Libelius R., Thesleff S. Neuromuscular Junction. 1989;65-76 Elsevier, Amsterdam.
24. Pereira E.F., Reinhardt-Maelicke S., Schrattenholz A., Maelicke A., Albuquerque E.X. Identification and functional characterization of a new agonist site on nicotinic acetylcholine receptors of cultured hippocampal neurons. Journal of Pharmacology and Experimental Therapeutics. 265:1993;1474-1491.
25. Perry E.K., Haroutunian V., Davis K.L., Levy R., Lantos P., Eagger S., Honavar M., Dean A., Griffiths M., McKeith I.G. Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimer's disease. Neuroreport. 5:1994;747-749.
26. Perry E.K., Morris C.M., Court J.A., Cheng A., Fairbairn A.F., McKeith I.G., Irving D., Brown A., Perry R.H. Alterations in nicotine binding sites in Parkinson's disease, Lewy body dementia and Alzheimer's disease: possible index of early neuropathology. Neuroscience. 64:1995;385-395.
27. Raskind M., Peskind E.R., Wessel T., Yuan W. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology. 54:2000;2261-2268.
28. Raskind M., Truyen L. Galantamine has cognitive benefits for patients with Alzheimer's disease after 36 months of continuous treatment. Eighth International Conference of Alzheimer's Disease and Related Disorders, Stockholm: 2002;. abst. 429.
29. Robinson J.P., Darzynkiewicz Z., Dean P.N., Orfao A., Rabinovitch P.S., Stewart C.C., Tanke H.J., Weeless L.L. Current Protocols in Cytometry. 1997;John Wiley & Sons, Inc. New York.
30. Rusted J.M., Newhouse P.A., Levin E.D. Nicotinic treatment for degenerative and neuropsychiatric disorders such as Alzheimer's disease and Parkinson's disease. Behavior Brain Research. 113:2000;121-129.
31. Samochocki M., Zerlin M., Jostock R., Groot-Kormelink P.J., Luyten W.H., Albuquerque E.X., Maelicke A. Galantamine is an allosterically potentiating ligand of the human alpha4/beta2 nAChR. Acta Neurologica Scandinavia. 176:(Suppl.):2000;68-73.
32. Santos M.D., Alkondon M., Pereira E.F., Aracava Y., Eisenberg H.M., Maelicke A., Albuquerque E.X. The nicotinic allosteric potentiating ligand galantamine facilitates synaptic transmission in the mammalian central nervous system. Molecular Pharmacology. 61:2002;1222-1234.
33. Schrattenholz A., Pereira E.F., Roth U., Weber K.H., Albuquerque E.X., Maelicke A. Agonist responses of neuronal nicotinic acetylcholine receptors are potentiated by a novel class of allosterically acting ligands. Molecular Pharmacology. 49:1996;1-6.
34. Shimohama S., Kihara T. Nicotinic receptor-mediated protection against β-amyloid neurotoxicity. Biological Psychiatry. 49:2001;233-239.
35. Shimohama S., Greenwald D.L., Shafron D.H., Akaika A., Maeda T., Kaneko S., Kimura J., Simpkins C.E., Day A.L., Meyer E.M. Nicotinic alpha 7 receptors protect against glutamate neurotoxicity and neuronal ischemic damage. Brain Research. 779:1998;359-363.
36. Sjödin C., Jedenius E., Andreasen N. Four year treatment with galantamine in Swedish patients with Alzheimer disease. Eighth International Conference Alzheimer's Disease and Related Disorders, Stockholm: 2002;. abst. 348.
37. Soto C., Castasno E., Frangione B., Inestrosa N. The alpha-helical to beta-stand transition in the amino-terminal fragment of the amyloid beta-peptide modulates amyloid formation. Journal of Biological Chemistry. 270:1995;3063-3067.
38. Storch A., Schrattenholz A., Cooper J.C., Abdel Ghani E.M., Gutbrod O., Weber K.H., Reinhardt S., Lobron C., Hermsen B., Soskic V. Physosotigmine, galantamine and codeine act as noncompetitive nicotinic receptor agonists on clonal rat pheochromocytoma cells. European Journal of Pharmacology. 290:1995;207-219.
39. Tariot P.N., Solomon P.R., Morris J.C., Kershaw P., Lilienfeld S., Ding C. A month, randomized, placebo-controlled trial of galantamine in AD. Neurology. 54:2000;2269-2276.
40. Thomsen T., Kaden B., Fischer J.P.B., Bickel U., Barz H., Cervos-Navarro J., Kewitz H. Inhibition of acetylcholinesterase activity in human brain tissue and erythrocytes by galantamine, physostigmine and tacrine. European Journal of Chemistry and Clinical Biochemistry. 29:1991;487-492.
41. Tomski S., Murphy R. Kinetics of aggregation of synthetic beta-amyloid peptide. Archives in Biochemistry and Biophysics. 294:1992;630-638.
42. Wang H.Y., Lee D.H., Davis C.B., Shank R.P. Amyloid peptide Abeta(1-42) binds selectively and with picomolar affinity to alpha-7 nicotinic acetylcholine receptors. Journal of Neurochemistry. 75:2000;1155-1161.
43. Wang H.Y., Lee D.H., D'Andrea M.R., Peterson P.A., Shank R.P., Reitz A.B. Beta-Amyloid(1-42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology. Journal of Biological Chemistry. 275:2000;5626-5632.
44. Wei H., Wei W., Bredesen D.E., Perry D.C. Bcl-2 protects against apoptosis in neuronal cell line caused by thapsigargin induced depletion of intracellular calcium stores. Journal of Neurochemistry. 70:1998;2305-2314.
45. Wilcock G.K., Lilienfeld S., Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicenter randomised controlled trial. Galantamine International-1 Study Group. BMJ. 321:2000;1445-1449.
46. Yamashita H., Nakamura S. Nicotine rescues PC12 cells from death induced by nerve growth factor deprivation. Neuroscience Letters. 213:1996;145-147.